Mobile

Safety study of oral azacitidine (CC-486) in patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes experiencing no symptom of the disease after stem cell transplantation

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-005805-36

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To determine the maximal tolerated dose (MTD) of oral azacitidine in subjects with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after allogeneic hematopoietic stem cell transplantation (HSCT).

Critère d'inclusion

  • Subjects with acute myeloid leukemia or myelodysplastic syndromes in morphological remission after allogeneic hematopoietic stem cell transplantation

Liens